# US 2021/0275685 A1 · Immunoconjugates targeting adam9 and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275685 A1
- Document ID: US20210275685A1
- Status: Published application
- Kind: A1
- Application number: 17/255,064
- Filed: 2019-06-25
- Published: 2021-09-09
- Earliest claimed: 2018-06-26
- Assignees: ImmunoGen, Inc.; MacroGenics, Inc.
- Applicants: Immunogen, Inc.; Macrogenics, Inc.
- Inventors: Stuart William Hicks; Nicholas C. Yoder; Bhaswati Barat; Ezio Bonvini; Gundo Diedrich; Leslie S. Johnson; Deryk Loo; Juniper A. Scribner
- Web page: https://patentgrep.com/patent/US20210275685A1

## CPC

- A61K 47/6871: {the antibody targeting an enzyme}
- A61K 31/5365: ortho- or peri-condensed with heterocyclic ring systems
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/68033: {the drug being a maytansine}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/40: against enzymes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention is directed to immunoconjugates comprising an antibody or fragment thereof capable of specifically binding to “Disintegrin and Metalloproteinase Domain- containing Protein 9” (“ADAM9”) conjugated to at least one maytansinoid compound. The invention particularly concerns such immunoconjugates that are cross-reactive with human ADAM9 and the ADAM9 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to all such immunoconjugates that comprise a Light Chain Variable (VL) Domain and/or a Heavy Chain Variable (VH) Domain that has been humanized and/or deimmunized so as to exhibit reduced immunogenicity upon administration of such immunoconjugate to a recipient subject. The invention is also directed to pharmaceutical compositions that contain any of such immunoconjugates, and to methods involving the use of any of such immunoconjugates in the treatment of cancer and other diseases and conditions.

## Claims

### Claim 1

An immunoconjugate represented by the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
CB is an anti-ADAM9 antibody or ADAM9-binding fragment thereof;
L2 is represented by one of the following formula:
wherein:
Rx, Ry, Rx′ and Ry′, for each occurrence, are independently H, —OH, halogen, —O—(C1-4 alkyl), —SO3H, —NR40R41R42+, or a C1-4 alkyl optionally substituted with —OH, halogen, SO3H or NR40R41R42+, wherein R40, R41 and R42 are each independently H or a C1-4 alkyl;
l and k are each independently an integer from 1 to 10;
l1 is an integer from 2 to 5;
k1 is an integer from 1 to 5; and
s1 indicates the site connected to the cell-binding agent CB and s3 indicates the site connected to the A group;
A is an amino acid residue or a peptide comprising 2 to 20 amino acid residues;
R1 and R2 are each independently H or a C1-3alkyl;
L1 is represented by the following formula:
—CR3R4—(CH2)11-8—C(═O—
wherein R3 and R4 are each independently H or Me, and the —C(═O)— moiety in L1 is connected to D;
D is represented by the following formula:
and
q is an integer from 1 to 20.

### Claim 2 (depends on 1)

The immunoconjugate of claim 1, wherein R1, Rx, Rx′ and R′ are all H; and 1 and k are each independently an integer an integer from 2 to 6.

### Claim 3 (depends on 1, 2)

The immunoconjugate of claim 1 or 2, wherein A is a peptide containing 2 to 5 amino acid residues.

### Claim 4 (depends on 3)

The immunoconjugate of claim 3, wherein A is selected from the group consisting of Gly-Gly-Gly, Ala-Val, Val-Ala, D-Val-Ala, Val-Cit, D-Val-Cit, Val-Lys, Phe-Lys, Lys-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Ile-Cit, Phe-Ala, Phe-N9-tosyl-Arg, Phe-N9-nitro-Arg, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Leu-Ala-Leu, Ile-Ala-Leu, Val-Ala-Val, Ala-Ala-Ala, D-Ala-Ala-Ala, Ala-D-Ala-Ala, Ala-Ala-D-Ala, Ala-Leu-Ala-Leu (SEQ ID NO: 144), β-Ala-Leu-Ala-Leu (SEQ ID NO: 145), Gly-Phe-Leu-Gly (SEQ ID NO: 146), Val-Arg, Arg-Arg, Val-D-Cit, Val-D-Lys, Val-D-Arg, D-Val-Cit, D-Val-Lys, D-Val-Arg, D-Val-D-Cit, D-Val-D-Lys, D-Val-D-Arg, D-Arg-D-Arg, Ala-Ala, Ala-D-Ala, D-Ala-Ala, D-Ala-D-Ala, Ala-Met, Gln-Val, Asn-Ala, Gln-Phe, Gln-Ala, D-Ala-Pro, and D-Ala-tBu-Gly, wherein the first amino acid in each peptide is connected to L2 group and the last amino acid in each peptide is connected to —NH—CR1R2—S—L1-D.

### Claim 5 (depends on 1, 2, 3, 4)

The immunoconjugate of any one of claims 1-4, wherein R1 and R2 are both H.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The immunoconjugate of any one of claims 1-5, wherein L1 is —(CH2)4-6-C(═O)—.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The immunoconjugate of any one of claims 1-6, wherein D is represented by the following formula:

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The immunoconjugate of any one of claims 1-7, wherein the immunoconjugate is represented by the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
is the anti-ADAM9 antibody or ADAM9-binding fragment thereof connected to the L2 group through a Lys amine group;
is the anti-ADAM9 antibody or ADAM9-binding fragment thereof connected to the L2 group through a Cys thiol group;
R3 and R4 are each independently H or Me;
m1, m3, n1, r, s1 and t1 are each independently an integer from 1 to 6;
m2, n2, r2, s2 and t2 are each independently an integer from 1 to 7;
t3 is an integer from 1 to 12;
D1 is represented by the following formula:

### Claim 9 (depends on 8)

The immunoconjugate of claim 8, wherein the immunoconjugate is represented by the following formula:
wherein:
m1 and m3 are each independently an integer from 2 to 4;
m2 is an integer from 2 to 5;
r1 is an integer from 2 to 6; and
r2 is an integer from 2 to 5.

### Claim 10 (depends on 8, 9)

The immunoconjugate of claim 8 or 9, wherein A is Ala-Ala-Ala, Ala-D-Ala-Ala, Ala-Ala, D-Ala-Ala, Val-Ala, D-Val-Ala, D-Ala-Pro, or D-Ala-tBu-Gly.

### Claim 11 (depends on 8)

The immunoconjugate of claim 8, wherein the immununoconjugate is represented by the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
A is Ala-Ala-Ala, Ala-D-Ala-Ala, Ala-Ala, D-Ala-Ala, Val-Ala, D-Val-Ala, D-Ala-Pro, or D-Ala-tBu-Gly, and
D1 is represented by the following formula:

### Claim 12 (depends on 11)

The immunoconjugate of claim 11, wherein the immunoconjugate is represented by the following formula:
wherein D1 is represented by the following formula:

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The immunoconjugate of any one of claims 1-12, wherein the immunoconjugate comprises a humanized anti-ADAM9 antibody or ADAM9-binding fragment thereof that specifically binds to human ADAM9 and cyno ADAM9 wherein said humanized anti-ADAM9 antibody or ADAM9-binding fragment thereof is conjugated to the pharmacological agent.

### Claim 14 (depends on 13)

The immunoconjugate of claim 13, wherein said humanized anti-ADAM9 antibody or ADAM9-binding fragment thereof comprises a CDRH1 domain, a CDRH2 domain, and a CDRH3 domain and a CDRL1 domain, a CDRL2 domain, and a CDRL3 domain having the sequences selected from the group consisting of:
(a) SEQ ID NOs: 8, 35, and 10 and SEQ ID NOs: 62, 13, 14, respectively;
(b) SEQ ID NOs: 8, 35, and 10 and SEQ ID NOs: 63, 13, 14, respectively;
(c) SEQ ID NOs: 8, 36, and 10 and SEQ ID NOs: 63, 13, 14, respectively; and
(d) SEQ ID NOs: 34, 36, and 10 and SEQ ID NO:64, 13, 65, respectively.

### Claim 15 (depends on 13, 14)

The immunoconjugate of claim 13 or 14, wherein said humanized anti-ADAM9 antibody or ADAM9-binding fragment thereof comprises a heavy chain variable domain (VH) and a light chain variable domain (VL) having sequences that are at least 90%, at least 95%, or at least 99% identical to sequences selected from the group consisting of:
(a) SEQ ID NO:17 and SEQ ID NO:55, respectively;
(b) SEQ ID NO:17 and SEQ ID NO:56, respectively;
(c) SEQ ID NO:18 and SEQ ID NO:56, respectively; and
(d) SEQ ID NO:19 and SEQ ID NO:57, respectively.

### Claim 16 (depends on 15)

The immunoconjugate of claim 15, wherein said humanized anti-ADAM9 antibody or ADAM9-binding fragment thereof comprises a heavy chain variable domain (VH) and a light chain variable domain (VL) having the sequences selected from the group consisting of:
(a) SEQ ID NO:17 and SEQ ID NO:55, respectively;
(b) SEQ ID NO:17 and SEQ ID NO:56, respectively;
(c) SEQ ID NO:18 and SEQ ID NO:56, respectively; and
(d) SEQ ID NO:19 and SEQ ID NO:57, respectively.

### Claim 17 (depends on 13)

The immunoconjugate of claim 13, wherein said humanized anti-ADAM9 antibody or ADAM9-binding fragment thereof is optimized to have at least a 100-fold enhancement in binding affinity to cyno ADAM9 and retains high affinity binding to human ADAM9 as compared to the chimeric or murine parental antibody.

### Claim 18 (depends on 17)

The immunoconjugate of claim 17, wherein said anti-ADAM9 antibody or ADAM9-binding fragment thereof comprises a CDRH1 domain, a CDRH2 domain, and a CDRH3 domain and a CDRL1 domain, a CDRL2 domain, and a CDRL3 domain having the sequences selected from the group consisting of:
(a) SEQ ID NOs: 8, 35, and 37 and SEQ ID NOs: 62, 13, 14, respectively;
(b) SEQ ID NOs: 8, 35, and 38 and SEQ ID NOs: 62, 13, 14, respectively;
(c) SEQ ID NOs: 8, 35, and 39 and SEQ ID NOs: 62, 13, 14, respectively;
(d) SEQ ID NOs: 8, 35, and 40 and SEQ ID NOs: 62, 13, 14, respectively;
(e) SEQ ID NOs: 8, 35, and 41 and SEQ ID NOs: 62, 13, 14, respectively;
(f) SEQ ID NOs: 8, 35, and 42 and SEQ ID NOs: 62, 13, 14, respectively;
(g) SEQ ID NOs: 8, 35, and 43 and SEQ ID NOs: 62, 13, 14, respectively;
(h) SEQ ID NOs: 8, 35, and 44 and SEQ ID NOs: 62, 13, 14, respectively;
(i) SEQ ID NOs: 8, 35, and 45 and SEQ ID NOs: 62, 13, 14, respectively; and
(j) SEQ ID NOs: 8, 35, and 46 and SEQ ID NOs: 62, 13, 14, respectively.

### Claim 19 (depends on 18)

The immunoconjugate of claim 18, wherein said humanized anti-ADAM9 antibody or ADAM9-binding fragment thereof comprises a heavy chain variable domain (VH) and a light chain variable domain (VL) having sequences that are at least 90%, at least 95%, or at least 99% identical to sequences selected from the group consisting of:
(a) SEQ ID NO:20 and SEQ ID NO:55, respectively;
(b) SEQ ID NO:21 and SEQ ID NO:55, respectively;
(c) SEQ ID NO:22 and SEQ ID NO:55, respectively;
(d) SEQ ID NO:23 and SEQ ID NO:55, respectively;
(e) SEQ ID NO:24 and SEQ ID NO:55, respectively;
(f) SEQ ID NO:25 and SEQ ID NO:55, respectively;
(g) SEQ ID NO:26 and SEQ ID NO:55, respectively;
(h) SEQ ID NO:27 and SEQ ID NO:55, respectively;
(i) SEQ ID NO:28 and SEQ ID NO:55, respectively; and
(j) SEQ ID NO:29 and SEQ ID NO:55, respectively.

### Claim 20 (depends on 19)

The immunoconjugate of claim 19, wherein said humanized anti-ADAM9 antibody or ADAM9-binding fragment thereof comprises a heavy chain variable domain (VH) and a light chain variable domain (VL) having the sequences selected from the group consisting of:
(a) SEQ ID NO:20 and SEQ ID NO:55, respectively;
(b) SEQ ID NO:21 and SEQ ID NO:55, respectively;
(c) SEQ ID NO:22 and SEQ ID NO:55, respectively;
(d) SEQ ID NO:23 and SEQ ID NO:55, respectively;
(e) SEQ ID NO:24 and SEQ ID NO:55, respectively;
(f) SEQ ID NO:25 and SEQ ID NO:55, respectively;
(g) SEQ ID NO:26 and SEQ ID NO:55, respectively;
(h) SEQ ID NO:27 and SEQ ID NO:55, respectively;
(i) SEQ ID NO:28 and SEQ ID NO:55, respectively; and
(j) SEQ ID NO:29 and SEQ ID NO:55, respectively.

### Claim 21 (depends on 13, 14, 15, 16, 17, 18, 19, 20)

The immunoconjugate of any one of claims 13-20, wherein said humanized anti-ADAM9 antibody is a full length antibody comprising an Fc region.

### Claim 22 (depends on 21)

The immunoconjugate of claim 21, wherein said humanized anti-ADAM9 antibody comprises a heavy chain and a light chain having the sequences selected from the group consisting of:
(a) SEQ ID NO:50 and SEQ ID NO:68, respectively;
(b) SEQ ID NO:51 and SEQ ID NO:68, respectively; and
(c) SEQ ID NO:52 and SEQ ID NO:68, respectively.

### Claim 23 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The immunoconjugate of any one of claims 13-22, wherein said Fc region is a variant Fc region that comprises:
(a) one or more amino acid modification(s) that reduces(s) the affinity of the variant Fc region for an FcγR selected from the group consisting of: L234A, L235A, and L234A and L235A; and/or
(b) an amino acid modification that introduces a cysteine residue at S442, wherein said numbering is that of the EU index as in Kabat; and/or
(c) one or more amino acid substitution(s) that extend(s) the half-life of the variant Fc region for FcRn selected from the group consisting of: M252Y, S254T, and T256E.

### Claim 24 (depends on 18)

The immunoconjugate of claim 18, wherein said humanized anti-ADAM9 antibody comprises a heavy chain and a light chain having the sequences selected from the group consisting of:
(a) SEQ ID NO:141 and SEQ ID NO:68, respectively;
(b) SEQ ID NO:142 and SEQ ID NO:68, respectively;
(c) SEQ ID NO:143 and SEQ ID NO:68, respectively;
(d) SEQ ID NO:151 and SEQ ID NO:68, respectively;
(e) SEQ ID NO:152 and SEQ ID NO:68, respectively;
(f) SEQ ID NO:153 and SEQ ID NO:68, respectively; and
(g) SEQ ID NO:154 and SEQ ID NO:68, respectively.

### Claim 25 (depends on 24)

The immunoconjugate of claim 24, wherein X in SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153 or SEQ ID NO:154 is lysine.

### Claim 26 (depends on 24)

The immunoconjugate of claim 24, wherein X in SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:151, SEQ ID NO:152, SEQ ID NO:153 or SEQ ID NO:154 is absent.

### Claim 27 (depends on 1)

The immunoconjugate of claim 1, wherein the immunoconjugate is represented by the following formula:
wherein:
CBA is a humanized anti-ADAM9 antibody or ADAM9-binding fragment thereof comprising a CDRH1 domain, a CDRH2 domain, and a CDRH3 domain and a CDRL1 domain, a CDRL2 domain, and a CDRL3 domain having the sequences of SEQ ID NOs: 8, 35, and 45 and SEQ ID NOs: 62, 13, 14, respectively;
q is 1 or 2;
D1 is represented by the following formula:

### Claim 28 (depends on 27)

The immunoconjugate of claim 27, wherein said humanized anti-ADAM9 antibody or ADAM9-binding fragment thereof comprises a heavy chain variable domain (VH) and a light chain variable domain (VL) having sequences of SEQ ID NO:28 and SEQ ID NO:55, respectively.

### Claim 29 (depends on 27)

The immunoconjugate of claim 27, wherein said humanized anti-ADAM9 antibody comprises a heavy chain and a light chain having the sequences of SEQ ID NO:142 and SEQ ID NO:68, respectively.

### Claim 30 (depends on 27)

The immunoconjugate of claim 27, wherein said humanized anti-ADAM9 antibody comprises a heavy chain and a light chain having the sequences of SEQ ID NO:152 and SEQ ID NO:68, respectively.

### Claim 31 (depends on 29, 30)

The immunoconjugate of claim 29 or 30, wherein X in SEQ ID NO:142 or SEQ ID NO:152 is lysine.

### Claim 32 (depends on 29)

The immunoconjugate of claim 29, wherein X in SEQ ID NO:142 is absent.

### Claim 33 (depends on 27)

The immunoconjugate of claim 27, wherein said humanized anti-ADAM9 antibody comprises a heavy chain and a light chain having the sequences of SEQ ID NO:156 and SEQ ID NO:68, respectively.

### Claim 34 (depends on 1)

The immunoconjugate of claim 1, wherein the immunoconjugate is represented by the following formula:
wherein:
CBA is an humanized anti-ADAM9 antibody or ADAM9-binding fragment thereof comprising a CDRH1 domain, a CDRH2 domain, and a CDRH3 domain and a CDRL1 domain, a CDRL2 domain, and a CDRL3 domain having the sequences of SEQ ID NOs: 8, 35, and 45 and SEQ ID NOs: 62, 13, 14, respectively;
q is an integer from 1 or 10;
D1 is represented by the following formula:

### Claim 35 (depends on 33)

The immunoconjugate of claim 33, wherein said humanized anti-ADAM9 antibody or ADAM9-binding fragment thereof comprises a heavy chain variable domain (VH) and a light chain variable domain (VL) having sequences of SEQ ID NO:28 and SEQ ID NO:55, respectively.

### Claim 36 (depends on 35)

The immunoconjugate of claim 35, wherein said humanized anti-ADAM9 antibody comprises a heavy chain and a light chain having the sequences of SEQ ID NO:52 and SEQ ID NO:68, respectively.

### Claim 37 (depends on 34)

The immunoconjugate of claim 34, wherein said humanized anti-ADAM9 antibody comprises a heavy chain and a light chain having the sequences of SEQ ID NO:151 and SEQ ID NO:68, respectively.

### Claim 38 (depends on 36, 37)

The immunoconjugate of claim 36 or 37, wherein X in SEQ ID NO:52 or SEQ ID NO:151 is lysine.

### Claim 39 (depends on 36)

The immunoconjugate of claim 36, wherein X in SEQ ID NO:52 is absent.

### Claim 40 (depends on 34)

The immunoconjugate of claim 34, wherein said humanized anti-ADAM9 antibody comprises a heavy chain and a light chain having the sequences of SEQ ID NO:155 and SEQ ID NO:68, respectively.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A pharmaceutical composition comprising an effective amount of the immunoconjugate of any of claims 1-40 and a pharmaceutically acceptable carrier, excipient or diluent.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

A method for treating a disease or condition associated with, or characterized by, the expression of ADAM9 in a subject comprising administering to said subject an effective amount of the immunoconjugate of any one of claims 1-40 or the pharmaceutical composition of claim 41.

### Claim 43 (depends on 42)

The method of claim 42, wherein said disease or condition associated with, or characterized by, the expression of ADAM9 is cancer.

### Claim 44 (depends on 43)

The method of claims 43, wherein said cancer is selected from the group consisting of non-small-cell lung cancer, colorectal cancer, bladder cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, prostate cancer, esophageal cancer, breast cancer, head and neck cancer, uterine cancer, ovarian cancer, liver cancer, cervical cancer, thyroid cancer, testicular cancer, myeloid cancer, melanoma, and lymphoid cancer.

### Claim 45 (depends on 44)

The method of claim 44, wherein said non-small-cell lung cancer is squamous cell carcinoma, nonsquamous cell carcinoma, adenocarcinoma, or large-cell undifferentiated carcinoma.

### Claim 46 (depends on 44)

The method of claim 44, wherein said colorectal cancer is adenocarcinoma, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, primary colorectal lymphoma, leiomyosarcoma, or squamous cell carcinoma.

### Claim 47 (depends on 42)

The method of claim 42, wherein the method is for treating non-small-cell lung cancer, gastric cancer, pancreatic cancer, triple negative breast cancer (TNBC) or colorectal cancer.
